Results 61 to 70 of about 60,158,519 (252)

Uncovering how interleukin-5 and interleukin-23 shape human immune defense against Salmonella enterica Typhi

open access: yesJournal of Microbiology and Infectious Diseases
Background: Salmonella enterica serotype Typhi remains a major global health concern, particularly in regions with limited resources. Interleukins such as interleukin-5 and interleukin-23 are thought to play pivotal roles in shaping the host's ...
Ruaa Kareem Surhan   +3 more
doaj   +1 more source

Interleukin-6 levels in the control and AAA groups.

open access: yes, 2023
There was no significant difference in plasma levels of IL-6 between groups (P = .17). AAA, abdominal aortic aneurysm; IL-6, interleukin-6.
Lenka Maliskova (8781746)   +14 more
core   +1 more source

Smaller is better: nanobodies meet NMR

open access: yesFEBS Letters, EarlyView.
Nanobodies are single‐domain antigen‐binding fragments derived from camelid heavy chain antibodies. Their small size, high stability, and exceptional specificity make nanobodies uniquely useful probes for NMR studies of protein dynamics, transient conformational states, and protein–protein interactions.
Oleg Y. Dmitriev
wiley   +1 more source

Perspectives on the Genetic Associations of Ankylosing Spondylitis

open access: yesFrontiers in Immunology, 2021
Ankylosing spondylitis (AS) is a common form of inflammatory spinal arthritis with a complex polygenic aetiology. Genome-wide association studies have identified more than 100 loci, including some involved in antigen presentation (HLA-B27, ERAP1, and ...
B. Paul Wordsworth   +6 more
doaj   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

open access: yesMolecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

open access: yesMolecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola   +11 more
wiley   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

open access: yesMolecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park   +6 more
wiley   +1 more source

Cancer‐associated mutations in endometriosis reframe a benign disease through molecular oncology

open access: yesMolecular Oncology, EarlyView.
This review aims to comprehensively analyse cancer‐associated somatic mutations (CAMs) present in endometriotic lesions, emphasizing their biological roles, spatial distribution and implications for translational applications in medicine. By contextualizing a benign state within a genomic framework, this analysis seeks to establish its value as a ...
Clarissa Mujacic   +15 more
wiley   +1 more source

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis

open access: yesDrug Design, Development and Therapy, 2018
Isabel M Haugh,1 Allie K Preston,2 Dario N Kivelevitch,1 Alan M Menter1 1Department of Dermatology, Baylor University Medical Center, Dallas, TX, USA; 2Texas A&M Health Science Center College of Medicine, Bryan, TX, USA Abstract: Risankizumab, a ...
Haugh IM   +3 more
doaj  

Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial

open access: yesDermatology and Therapy, 2023
Introduction Hidradenitis suppurativa (HS) is a chronic, immune-mediated skin condition characterized by inflammatory lesions that can cause pain, impaired physical activity, and reduced quality of life.
Alexa B. Kimball   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy